Author | Type | Age | N rhGH | Dose of rhGH | Period (years) | Country | Outcome |
Donze SH et al 15 | BEFORE AND AFTER | 6 months-3 years | 29 | 1 mg/m2/day | 3 | Netherlands | Psychomotor development (BSID-II - mental and motor development), head circumference |
Dykens EM et al 13 | COHORT (three separated studies) | 4–21 years | 96; 127; 168 | 1 mg/m2/day | 6, 2 | USA | BMI-SDS. Cognition: KBIT-2 (verbal IQ, non-verbal IQ, composite IQ) VABS-II (communication and daily live skills, socialisation, adaptive composite). Hyperphagia Questionnaire; Repetitive Behaviour Scale |
Bakker NE et al 10 | BEFORE AND AFTER | 6±4.3 years | 1566 | 0.23 mg/kg/week | 3 | KIGS database -worldwide | Z-stature, BMI-SDS, adverse effects |
Bakker NE et al 18 | BEFORE AND AFTER | 6–14 years | 76 | 1 mg/m2/day | 11 | Netherlands | Quality of life (DUX25 and DUXPW questionnaires) |
Scheermeyer E et al 47 | BEFORE AND AFTER | 13–24 months 2–12 years | 72 | 1 mg/m2/day | 3 | Australia | Z-stature, BMI-SDS and adverse effects |
Lo ST 201534 | COHORT | 3.5–14 years | 24 | 1 mg/m2/day | 2;8 | Netherlands | Behaviour. Developmental Behaviour Checklist of Children with intellectual disability (DBC) and Children's Social Behaviour Questionnaire (CSBQ) |
Lo ST et al 36 | COHORT | 3.5–14 years | 53 | 1 mg/m2/day | 2;7 | Netherlands | VABS-II, Cognitive function: Bayley Scales of Infants II- NL (BSID-II), Wechsler Preschool and Primary Scale of Intelligence-Revised Dutch version |
Bakker NE et al 12 | BEFORE AND AFTER | 3–7 years (mean: 5.49) | 60 | 1 mg/m2/day | 8 | Netherlands | Z-stature, BMI-SDS, lean body mass-SDS, % fat mass-SDS, head circumference |
Meinhardt U et al 42 | COHORT | 0.4–12.2 years (mean:3.8) | 41 | 0.03 mg/kg/day | 1; 6 | Switzerland, Denmark, Germany | Z-stature, body composition and adverse effects |
Siemensma EPC et al 14 | COHORT | 3.5–14 years | 29 | 1 mg/m2/day | 2; 4 | Netherlands | WISC-R (vocabulary, similarities, block design and picture arrangement) and Wechsler Preschool and Primary Scale of Intelligence-Revised Dutch version - less 7 years old |
Colmenares A et al 48 | COHORT | 1–15 years (mean: 6±3.7) | 36 | 0.03 mg/kg/day | 3 | France | Z-stature, BMI-SDS and body composition- lean mass (kg)/ %fat mass |
Sipilä I et al 39 | BEFORE AND AFTER | 2.0–10.3 years (mean: 6.6) | 20 | 0.033 mg⁄kg⁄ day | 1; 10 | Finland | Z-stature, BMI-SDS, body composition (%fat), and quality of life (HRQOL) |
Carrel AL et al 8 | COHORT | 4–32 months/. 6–9 years | 46 | 1 mg/m2/day | 6 | USA | Z-stature, body composition and muscular strength |
de Lind van Wijngaarden RFA et al 9 | BEFORE AND AFTER | 5.9±3.2 years | 55 | 1 mg/m2/day | 4 | Netherlands | Z-stature, BMI-SDS, body composition (%fat-SDS and lean body mass- SDS), head circumference |
Nyunt O et al 49 | COHORT | <3 years and >3 years | 54 | 0,6 mg/m2/day | 4 | Australia | Z-stature and BMI-SDS |
Lindgren AC et al 50 | BEFORE AND AFTER | 4.9–11.3 years (mean 6.9) | 22 | 0.03 mg/kg/day | 10 | Sweden | Z-stature, BMI-SDS and body composition |
Lin H-Y et al 51 | BEFORE AND AFTER | 1.3–13.5 years | 46 | 0.01 U/kg/day | 5 | Taiwan | Z-stature, BMI-SDS and adverse effects |
Angulo MA et al 43 | COHORT | 8.3±2.7 years | 21 | 0.25 mg/kg/week | 7.9 | USA | Z-stature and BMI-SDS |
Carrel AL et al 40 | BEFORE AND AFTER | 12 years | 48 | 1 mg/m2/day | 4 | USA | Z-stature, body composition, muscular strength, adverse effects |
Tauber M et al 52 | BEFORE AND AFTER | 8.4±3.2 years | 14 | 0.5 U/kg/week | 3.6 | France | Z- stature SDS, BMI-SDS, growth velocity |
BMI, body mass index; rhGH, recombinant human GH; SDS, SD scores.